The importance of clinical measures of adiposity (such as body-mass index [BMI], waist circumference, and waist-to-hip ratio) in calculating cardiovascular risk remains controversial. For example, both the World Health Organisation and the United States National Heart, Lung and Blood Institute recommend assessment of BMI, however several common cardiovascular disease risk scores (e.g. PROCAM) omit adiposity […]
Tag: cardiovascular risk
Adolescent BMI predicts future cardiovascular risk
The emerging pandemic of obesity is threatening to reverse the gains in cardiovascular mortality and morbidity that have occurred during the latter half of the 20th century. While adult obesity is clearly related to cardiovascular risk the association of body-mass index (BMI) in adolescence to future adult cardiovascular disease has not been completely delineated. […]
Cardiovascular risk of rofecoxib persists after discontinuation
After the use of rofecoxib was associated with an increased risk of cardiovascular events in the APPROVe (Adenomatous Polyp Prevention on Vioxx) trial, the drug was withdrawn from the worldwide market in 2004. A 1-year period of postdrug observation has already revealed an increased cardiovascular risk even after stopping treatment, therefore the aim of this […]
Effective Risk-Factor Reduction Could Eliminate Socioeconomic differences in cardiovascular health
A socioeconomic gradient in coronary mortality is well established in developed countries, and is becoming increasingly apparent in low- and middle-income countries too. Previously, it has not been clear to what extent the classical cardiovascular risk factors are responsible for this difference, nor indeed whether by treating them effectively it could be possible to balance […]
New APPROVE data confirm vioxx cardiovascular risk
In September 2004 the APPROVe (Adenomatous Polyp Prevention on Vioxx) trial was stopped early due to concerns about increased cardiovascular mortality in patients taking the drug. An analysis of the long-term outcomes of the patients in the trial has now been published in the Lancet. […]